Physician profile
Steven A Oginsky
NPI 1932447687
$482.63
in general payments reported to CMS, 2019-2025
11 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.48 · 2022: $113 · 2023: $32.06 · 2024: $105 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.80 | 2022-2025 | Ozempic, Rybelsus, Saxenda |
| Abbvie INC. | $87.92 | 2021-2025 | |
| Welch Allyn | $57.00 | 2021 | |
| Lilly USA, LLC | $54.08 | 2021-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $48.79 | 2024-2025 | Gardasil 9, Gardasil, Enflonsia |
| Supernus Pharmaceuticals, INC. | $35.19 | 2022-2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2022 | |
| Collegium Pharmaceutical, INC. | $20.01 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $19.25 | 2025 | The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $17.25 | 2023 | Ingrezza |
| Glaxosmithkline, LLC. | $15.93 | 2024 | Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Oginsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.